Stockysis — AI-Powered Stock News & Sentiment Analysis

Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $15 to $19.

Comments

No comments yet. Be the first!